Senzime, a medical device company, agreed to acquire Respiratory Motion, a medtech company, for $44m. ”This is an acquisition with perfect logic. Respiratory Motion gives us the conditions to further accelerate the rollout of TetraGraph while expanding our business of monitoring patients' respiratory function outside the operating room. With Respiratory Motion's unique system, we reach three times as large patient volume and lay the next building block in our journey to be the market leader in precision-based monitoring of vital signs with the overarching mission of eliminating anesthesia and sedation-related complications.” Pia Renaudin, Senzime CEO.